Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials

OBJECTIVE: Although dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab, has shown promising results in patients with HER2-positive breast cancer (BC), it is still unclear whether dual therapy will increase adverse effects (AEs) while ensuring the efficacy compared with trastuzumab monothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyun, Fang, Yingying, Li, Yinjuan, Li, Yan, Qi, Lu, Wang, Xinghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555237/
https://www.ncbi.nlm.nih.gov/pubmed/36249045
http://dx.doi.org/10.3389/fonc.2022.894861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555237/
https://www.ncbi.nlm.nih.gov/pubmed/36249045
http://dx.doi.org/10.3389/fonc.2022.894861

Ejemplares similares